Most of us have experienced anxiety or will at some point in the future. It's normal to feel worried from time to time.

Supplementary insurance coverage for complementary health services (Yes) 202 55.0 Has a family physician (Yes) 308 83.5 Comorbid anxiety disorder ... professional of GAD in the past 12 months ...

We are delighted to welcome Dr. Barbato to Incannex as our Chief Medical Officer. With an established track record in directing drug development through late-stage clinical trials and multiple product ...

The Boston-based biotech will use the new fundraise to develop its pipeline of drug candidates for conditions such as major ...

AbbVie has returned to the source of its antipsychotic powerhouse Vraylar in search of another blockbuster, paying $25 ...

He joins Incannex as the company continues to advance its lead clinical-stage programs in obstructive sleep apnea, generalized anxiety disorder, and rheumatoid arthritis. "We are delighted to welcome ...

A Duloxetine recall by the FDA has flagged more than 7,100 bottles of the Cymbalta generic drug due to a cancerous chemical.

A prescription digital therapeutic for insomnia was associated with significant improvements in sleep, depression, and anxiety.

AbbVie (ABBV) and Gedeon Richter announced a new discovery, co-development and license agreement to advance novel targets for the potential ...

N-nitroso-duloxetine belongs to the nitrosamine class of compounds, some of which are classified as probable or possible human carcinogens.

Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel ...